10-Q: AppYea Inc. Reports Q1 2025 Financial Results, Cites Ongoing Development and Commercialization Efforts

AppYea Inc. reports a net loss of $166,000 for Q1 2025, focusing on the development and commercialization of its AppySleep product line.

Summary

• AppYea Inc. filed its Form 10-Q for the quarter ended March 31, 2025.
• The company is focused on developing wearable monitoring solutions for sleep apnea and snoring.
• AppYea reported revenues of $3,000 for Q1 2025, compared to $13,000 in Q1 2024.
• The company's net loss for the quarter was $166,000, a significant decrease from the $1,244,000 loss in the same period last year.
• Research and development expenses decreased to $6,000 from $60,000 year-over-year.
• General and administrative expenses also decreased to $111,000 from $294,000 year-over-year.
• As of March 31, 2025, AppYea had $95,000 in cash and cash equivalents.
• The company has an accumulated deficit of $10,524,000 and a stockholders deficiency of $4,179,000.
• AppYea's management believes current funds will sustain operations through the end of the second quarter of 2025.
• The company is seeking additional capital through debt and equity securities.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company is preparing for sales of its AppySleep product during the second quarter of 2025.
• AppYea plans to file a 510(k) FDA submission for the AppySleep LAB app in 2026 and for AppySleep PRO in 2027.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company has reduced its losses and expenses, it faces significant financial challenges, including a large accumulated deficit and the need to raise additional capital. The going concern warning also weighs negatively on the sentiment.

Positives

• The net loss decreased significantly year-over-year, indicating improved cost management.
• Research and development expenses decreased, potentially reflecting a shift from development to commercialization.
• General and administrative expenses decreased, suggesting better operational efficiency.
• The company is preparing for sales of its AppySleep product in Q2 2025, indicating progress towards commercialization.
• The company received proceeds of $124,000 from the exercise of outstanding warrants at an exercise price of $0.0066 per share during the first quarter of 2025.

Negatives

• Revenues decreased from $13,000 in Q1 2024 to $3,000 in Q1 2025.
• The company has an accumulated deficit of $10,524,000 and a stockholders deficiency of $4,179,000.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's disclosure controls and procedures were not effective as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The development and regulatory approval processes for AppySleep LAB and AppySleep PRO are subject to risks and uncertainties.
• The company faces competition in the anti-snoring and sleep apnea treatment market.
• The company identified a material weakness in its controls related to segregation of duties and other immaterial weaknesses in several areas of data management and documentation.
• A lawsuit was filed in the Tel Aviv Magistrates Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary.

Future Outlook

The company intends to continue to finance its operating activities by raising capital and is preparing for sales of its AppySleep product during the second quarter of 2025. AppYea plans to file a 510(k) FDA submission for the AppySleep LAB app for the non-contact diagnosis of sleep apnea during 2026, and an FDA process for AppySleep PRO for the treatment of sleep apnea during 2027.

Management Comments

• Management believes that funds on hand will enable the company to fund operations and capital expenditure requirements through the end of the second quarter of 2025.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The global anti-snoring treatment market is expected to grow from USD 4.3 billion in 2020 to USD 8.6 billion by 2028, with a 9.07% CAGR between 2021 and 2028. The global sleep apnea device market was valued at USD 3.7 billion in 2020 and is expected to reach USD 6.1 billion by 2028, expanding at a CAGR of 6.2%.

Comparison to Industry Standards

• The document does not provide enough information to compare AppYea's results to specific industry standards or comparable companies.
• Without detailed financial metrics from competitors like ResMed, Philips Respironics, or other digital health companies in the sleep apnea space, a direct comparison is not possible.
• Additionally, the document lacks information on market share, customer acquisition costs, and other key performance indicators that would allow for a meaningful comparison to industry benchmarks.

Management Changes

Legal Proceedings

• A lawsuit was filed in the Tel Aviv Magistrates Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary.
• On April 10, 2025, the Company received a letter from its former Chief Executive Officer, who resigned as of January 19, 2025, alleging non-payment of amounts due him under his employment agreement.

Related Party Transactions

• During 2021, SleepX borrowed from Nexense Technologies USA. Inc., a Delaware corporation which is majority owned by Boris Molchadsky, the Companys Chairman.
• During 2020, the minority shareholder of Ta-nooma advanced a loan to Ta-nooma in the amount of NIS 115,725 .

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by cost reduction measures if the company is unable to secure sufficient funding.
• Customers may benefit from the development and commercialization of new products for sleep apnea and snoring.
• The company's ability to meet its obligations to suppliers and creditors is dependent on its financial performance and ability to raise capital.

Next Steps

• Prepare for sales of the AppySleep product during the second quarter of 2025.
• File a 510(k) FDA submission for the AppySleep LAB app in 2026.
• Pursue an FDA process for AppySleep PRO for the treatment of sleep apnea during 2027.
• Raise additional operating capital to maintain operations and realize the business plan.

Key Dates

Keywords

AppYea, AppySleep, Sleep apnea, Snoring, Wearable technology, Financial results, FDA approval, Digital health